Rezultati pretraživanja
  1. prije 21 minutu

    Ever wondered how to analyse the results of gene therapy experiments on brain and eye tissue much more easily and efficiently? Watch our 3rd-year students awesome presentation below. Full video and report:

    1 korisnik označava da mu se sviđa
  2. prije 22 minute

    Interim data from an ongoing of an investigational for has shown that a single administration of the treatment resulted in a complete cessation of bleeds up to the 26-week interim end point.

  3. prije 27 minuta

    Next month, is hosting a workshop focused on financing strategies to make and accessible and sustainable. Learn more and register here:

    1 korisnik označava da mu se sviđa
  4. prije 39 minuta

    Dr. Sowmya Viswanathan's is coming up on Feb. 20th! If you're interested in learning how to navigate the New Substance Notification Regulations for Organisms, register at our website:

  5. prije 48 minuta

    to buy cell and for $315m

  6. prije 2 sata

    Again and again at we hear the question, why is expression following so much more durable than ? Again and again we hear in reply.....

    1 proslijeđeni tweet 2 korisnika označavaju da im se sviđa
  7. prije 3 sata

    This significant contribution by Viralgen will go a long way to provide access to AAV manufacturing in order accelerate programs for ultra-rare diseases which has been a significant bottleneck in gene therapy.

  8. prije 3 sata

    4 hacks that allow you to push patient safety during cell and gene therapies to the next level. Check out our – our logistical solution for a successful CAR-T cell therapy!  _________

  9. prije 3 sata

    Great review about the history of gene therapy by Fran Leebeck from Eramus University (Rotterdam)

    1 proslijeđeni tweet 8 korisnika označava da im se sviđa
  10. prije 5 sati

    We are glad to announce that the first meeting will take place at TIGEM on 21-22 April 2020. We can’t wait to welcome the UPGRADE beneficiaries, share progress and plan future activities!

    4 korisnika označavaju da im se sviđa
  11. prije 5 sati

    Prof Pasi states the importance of discussing minimum factor expression expectations rather than means or medians in

    2 korisnika označavaju da im se sviđa
  12. prije 6 sati

    An interestingly a majority of the audience accept that an expressional lifespan of 10-15 years would be acceptable. Need to know whether that would be as acceptable to those recieveing the therapy.

    Prikaži ovu nit
    Prikaži ovu nit
  13. prije 7 sati

    A new report explores viral vectors, considered to be the linchpin of . Read the full article here:

  14. prije 7 sati

    [Infographic] We can’t believe that the first month of 2020 is already over! Reflecting back, 2019 was a great year for RoslinCT. Looking ahead, 2020 is already gearing up to be even better!

    2 proslijeđena tweeta 1 korisnik označava da mu se sviđa
  15. prije 8 sati

    We're here at Booth 22 at Cell and Gene Therapy Innovation Summit in Berlin - come and say hello!

  16. prije 20 sati

    Nice slide on capacity vs potential demand in NIH talk

    6 replies 6 proslijeđenih tweetova 30 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
  17. prije 21 sat

    Check out 's article with about programming "living medicines" for cell and gene therapies.

    10 proslijeđenih tweetova 19 korisnika označava da im se sviđa
  18. 3. velj

    With more than 900 investigational new drug applications for gene therapies currently in development, a new deluge of FDA final and draft guidances aim to accelerate development in the field of

  19. 3. velj

    Professor Keith Martin discusses his vision for new strategies to treat glaucoma with

    2 proslijeđena tweeta 2 korisnika označavaju da im se sviđa
  20. 3. velj

    Expecting huge recovery on oversold beaten down best in class and most promising Will only get higher from here if coronavirus stays relatively contained in US and outside China. and small plays in , data expected

    1 korisnik označava da mu se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.